Analyzing Questcor Pharmaceuticals (QCOR) and Sanofi (SNY)

Questcor Pharmaceuticals (NASDAQ: QCOR) and Sanofi (NYSE:SNY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.

Insider & Institutional Ownership

9.1% of Sanofi shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Questcor Pharmaceuticals and Sanofi, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Questcor Pharmaceuticals 0 0 0 0 N/A
Sanofi 2 6 2 0 2.00

Sanofi has a consensus target price of $51.50, indicating a potential upside of 14.93%.


This table compares Questcor Pharmaceuticals and Sanofi’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Questcor Pharmaceuticals N/A N/A N/A
Sanofi 25.44% 25.19% 14.09%

Earnings & Valuation

This table compares Questcor Pharmaceuticals and Sanofi’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Questcor Pharmaceuticals N/A N/A N/A N/A N/A
Sanofi $37.43 billion 3.02 $4.86 billion $2.24 20.00

Sanofi has higher revenue and earnings than Questcor Pharmaceuticals.


Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.5%. Questcor Pharmaceuticals does not pay a dividend. Sanofi pays out 49.1% of its earnings in the form of a dividend.


Sanofi beats Questcor Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

About Questcor Pharmaceuticals

Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Receive News & Ratings for Questcor Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Questcor Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply